Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

June 11, 2009 (Berlin, Germany) — The novel CD20 monoclonal antibody ofatumumab (Arzerra) has demonstrated superior response rates in 2 challenging groups of chronic lymphocytic leukemia (CLL) ...

Calquence and Venclexta, with or without Gazyva, improved PFS in untreated CLL patients compared to standard chemoimmunotherapy. The AMPLIFY trial showed reduced disease progression risk with the ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or ...

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash & 2026 catalysts—read now.

Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...